Loading…
Lobbying Spend
—
Filings
333
Firms Hired
5
Active Period
2005–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $25,000
Matched citations: H.R. 8800
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $25,000
Matched citations: S. 4784
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: THE NICKLES GROUP, LLC
S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $25,000
Matched citations: S. 4784
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 8800
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $40,000
Matched citations: S. 4784
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: THE NICKLES GROUP, LLC
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield, Opioid crisis legislation, naloxone access and awareness, H.R. 8800 / S. 4784, the FY27 National Defense Authorization Act provisions related to biological and chemical defense and access to naloxone.
Client expense: — · Firm income: $40,000
Matched citations: S. 4784
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · fourth_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · fourth_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
SUPPORT for Patients and Communities Reauthorization Act of 2025
2025 · fourth_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
2025 · fourth_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2483
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5252
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5252
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
SUPPORT for Patients and Communities Reauthorization Act of 2025
2025 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2483
SUPPORT for Patients and Communities Reauthorization Act of 2025
2025 · third_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 2483
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5252
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY26 Opioid crisis legislation, naloxone access and awareness State opioid response (SOR) Grant funding FY26 Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY26 Tribal Opioid Response Grant funding for FY26 NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025 H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025 H.R. 5252, HOPE Act
Client expense: — · Firm income: $50,000
Matched citations: H.R. 5252
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · second_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; Tribal Opioid Response Grant funding for FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · second_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; Tribal Opioid Response Grant funding for FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: THE NICKLES GROUP, LLC
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act, Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26, Opioid crisis legislation, naloxone access and awareness, FY2026 NDAA provisions related to biological and chemical defense and access to naloxone, H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Client expense: — · Firm income: $40,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025
2025 · first_quarter · Firm: ALPINE GROUP PARTNERS, LLC.
Reauthorization of Pandemic and All-Hazards Preparedness and Advancing Innovation Act; Funding for medical countermeasure enterprise including, Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY25 and FY26; Opioid crisis legislation, naloxone access and awareness; State opioid response (SOR) Grant funding FY25 and FY26; Substance Use Prevention, Treatment and Recovery Service Block Grant funding for FY25 and FY26; NDAA for Fiscal Year 2025 and Fiscal Year 2026 - provisions related to biological and chemical defense and access to naloxone; H.R. 1968, the Full-Year Continuing Appropriations and Extensions Act, 2025
Client expense: — · Firm income: $50,000
Matched citations: H.R. 1968
Preparing for All Hazards and Pathogens Reauthorization Act
2024 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
S. 2333, Pandemic and All-Hazards Preparedness and Response Act. H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2025. Opioid and heroin addiction legislation, naloxone access and awareness.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 4421
Pandemic and All-Hazards Preparedness and Response Act
2024 · fourth_quarter · Firm: THE NICKLES GROUP, LLC
S. 2333, Pandemic and All-Hazards Preparedness and Response Act. H.R. 4421, the Preparing for All-Hazards and Pathogen Reauthorization Act. Funding for medical countermeasure enterprise including Strategic National Stockpile (SNS), Biomedical Advanced Research and Development Authority (BARDA), and Project BioShield for FY2025. Opioid and heroin addiction legislation, naloxone access and awareness.
Client expense: — · Firm income: $40,000
Matched citations: S. 2333
Source: Senate LDA